Two-Pore-Domain Potassium (K2P-) Channels: Cardiac Expression Patterns and Disease-Specific Remodelling Processes
Key result
Two-pore-domain potassium channels, including TASK-1 and TREK-1, undergo disease-specific remodeling in atrial fibrillation and heart failure, highlighting their potential as therapeutic targets.
Why the study?
Alterations in K2P-channel expression and function in cardiovascular diseases suggest functional significance and therapeutic potential, but functional evidence for several channels in cardiac tissue remains sparse.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Should not yet alter AF or HF management; extends evidence for K2P channels as research targets.
Key Points
- This review summarizes the expression, function, and regulation of K2P channels in the cardiovascular system and their roles in disease.
- Describes K2P channel expression across different human cell types and organs.
- Compares disease-specific remodelling patterns with clinical findings.
- Discusses potential therapeutic roles of K2P channels, particularly in atrial fibrillation.
- Upregulation of K2P3.1 (TASK-1) in atrial fibrillation contributes to shortened action potential duration.
- K2P2.1 (TREK-1) currents are implicated in cardiac hypertrophy and fibrosis.
- Functional evidence for K2P channels in cardiac tissue remains limited, indicating a need for further investigation.
PICO
P
Population
Cardiovascular diseases
I
Intervention / Comparator
Two-pore-domain potassium (K2P) channels
This review summarizes the expression, function, and regulation of cardiovascular K2P channels, highlighting their potential as therapeutic targets in atrial fibrillation and heart failure.
Limitations
- Functional evidence of K2P channels in cardiac tissue remains sparse.
Cite This Study
Wiedmann et al. (2021) conducted a review in Cardiovascular diseases. Two-pore-domain potassium (K2P) channels was evaluated. Two-pore-domain potassium channels, including TASK-1 and TREK-1, undergo disease-specific remodeling in atrial fibrillation and heart failure, highlighting their potential as therapeutic targets.